2023年5月12日

Mindera健康™宣布改變行政領導團隊羅恩·羅卡成為首席執行官聖地亞哥,CA - 5月11日,2023 - Mindera健康™,心靈的開發人員。Px™,第一個實現精密醫學牛皮癬、行政領導團隊已經宣布了一項改變。該公司宣布行業資深羅恩·羅卡將接替喬治Mahaffey擔任總裁兼首席執行官。羅卡先生也將作為公司的董事。Mahaffey先生於2020年加入該公司,幫助公司的過渡從研發階段到Mindera健康的商業發射的第一個測試。“董事會的代表,我想感謝喬治Mindera健康價值的貢獻,”喬·庫克說,三世,主席Mindera健康和聯合創始人兼董事總經理山集團的合作夥伴。“我們都很感激,他執掌以來幫助我們完成,希望他最好的在他未來的事業。”“這是我的榮幸與這樣一個才華橫溢的專業團隊在過去三年中,協助將腦海中。Px精密醫學測試市場。祝公司所有,因為他們擴大這一重要的使用和創新技術,“Mahaffey先生說。“我非常興奮加入Mindera醫療團隊。總潛在市場超過20億美元僅在美國,腦海中。Px has the opportunity to enable huge improvements in patient care while reducing the overall healthcare spend on this disease. In addition to psoriasis, Mindera Health’s proprietary platform also provides access to rich biomarkers that will enable us to develop precision medicine tests for a wide range of diseases,” said Mr. Rocca. Mr. Cook went on to say, “We are very excited to have Ron join Mindera Health as we ramp up our commercial efforts with Mind.Px and advance a number of additional tests in our pipeline. Ron’s demonstrated commitment to help physicians improve patient care while driving commercial adoption and reimbursement aligns well with the mission of Mindera Health.” Mr. Rocca brings over two decades of biotech and diagnostics industry experience, including eleven years of developing and commercializing diagnostic products for autoimmune-related diseases. His prior role was President and CEO of Exagen Inc. (NASDAQ: XGN) which commercialized a suite of testing products enabling healthcare providers to improve care for patients through the differential diagnosis, prognosis, and monitoring of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Prior to Exagen, Mr. Rocca served as Vice President, Sales and Marketing, and as General Manager, at Prometheus Laboratories, Inc., a specialty pharmaceutical and diagnostic company focused on diseases in gastroenterology and oncology. He helped grow the company’s sales to $200 million-plus annually before playing an instrumental role in the $1.4 billion acquisition by Nestlé Health Science S.A. in 2011. Prior to Prometheus, Mr. Rocca was the General Manager of Alpharma Inc., a specialty pharmaceutical company. Earlier in his career, Mr. Rocca served in senior sales and marketing management positions for Elan Pharmaceuticals, Inc., a neuroscience-focused biotechnology company. Mr. Rocca received a B.A. in Marketing and Personnel Management from Towson University. Mr. Rocca will assume his new role at Mindera Health immediately. About Mind.Px™ Mind.Px is the flagship test of Mindera Health, designed to prospectively predict a patient’s response to expensive biologic drug classes prior to therapeutic selection and treatment. Using a scalable, minimally invasive dermal biomarker patch that captures over 7,000 biomarkers per sample along with data analytics, Mind.Px materially improves patient outcomes and significantly reduces healthcare system costs of expensive biologic treatments. About Mindera Health™ Mindera Health is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level. Using a proprietary dermal biomarker patch, next-generation sequencing, and machine learning, Mindera Health technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes. Mindera Health is a CLIA and CAP certified laboratory and has received ISO 13485:2016 certification. Find out more at www.minderahealth.com . About Mountain Group Partners Founded in 2002, Mountain Group Partners is a Nashville-based venture capital firm that invests in early-stage companies in the life sciences and disruptive technology sectors. The firm brings over 100 years of combined operational experience and has invested in more than 60 companies. www.mtngp.com ###